Embolization Pioneer Shines in Europe: CuraTech's Full-Stack Solution Debuts at ET 2026, Chinese Innovation Gains Global Recognition
Cardiolink Science
Vascular Interventional Medical Device Developer
In June 2026, the annual global gathering in the field of embolization therapy—the European Embolization Therapy Conference (ET 2026)—was grandly held in Valencia, Spain. AsThe Only Chinese Medical Device Company Invited to Attend the ConferenceCardiolink Science made a high-profile appearance with its full-stack product solutions, marking a leap from "participant" to "leader."— Mr. Che Haibo, Chairman of Cardiolink Science, was invited to deliver a special report, systematically presenting Cardiolink’s full-stack embolization solutions. The brand-sponsored satellite symposium was packed to capacity, with Chinese and international experts engaging in in-depth discussions on the frontiers of MSK embolization and the clinical application of Cardiolink’s products. An exhibition booth was set up to facilitate exchanges with global experts on advancements in embolization therapy and medical devices. Through its participation, Cardiolink showcased China’s cutting-edge capabilities in the field of interventional embolization to the world, emerging as a highly prominent Chinese force at this year’s conference.
I、ET 2026: The Global Benchmark for Embolization Therapy
ET is an annual professional conference on embolization therapy hosted by the Cardiovascular and Interventional Radiological Society of Europe (CIRSE). Since its inaugural edition in 2019, it has become the most important annual platform for interventional radiologists worldwide to learn and exchange knowledge on embolization therapies. The 2026 congress brought together more than a thousand experts and scholars from around the world, with a scientific agenda covering cutting-edge topics such as hepatocellular carcinoma, vascular malformations, and musculoskeletal and joint embolization. Chaired by Professor Pierleone Lucatelli, the program featured in-depth discussions on classic therapies as well as focused sessions on emerging technologies such as AI- and robot-assisted interventions. ET perfectly complements CIRSE’s existing educational framework, providing a vital platform for the innovation, education, and promotion of embolization therapy.
II- Cardiolink Science’s Participation: In-Depth Presence from Academic Presentations to Satellite Symposia
(I) Thematic Report: Sharing with Global Peers"The Chinese Solution"
During the conference, Mr. Che Haibo, Chairman of Cardiolink Science, was invited to deliver a presentation titled“Your TACE Co-pilot: Tailoring Solutions to the Physician's Touch”thematic report, conveying Cardiolink Science’s core philosophy to global experts in the field of embolization:Not Just a Simple Device Supplier, But a "Technical Partner" for Clinicians. The report systematically introduces Cardiolink Science's based on“Therapy Reading”A Full-Stack Embolization Solution Built on Core Concepts—From access devices to embolic microspheres, from permanent embolization to on-demand biodegradable embolization, and from tumor intervention to MSK embolization, Cardiolink Science has established a comprehensive product portfolio covering all scenarios of embolization therapy.In addition, the company shared its focus onEvidence-Based Medicine and Product Iteration Logic in the Field of TACE (Transarterial Chemoembolization). Mr. Che Haibo, from a physician’s perspective, elucidates how Cardiolink Science transforms clinical wisdom into precision medical tools, providing global operators withThe plug-and-play embolization therapy toolkit garnered extensive attention and high recognition from attending experts.
(II) Satellite Symposium: Focusing on TAMEFrontiers: Building an International Dialogue Platform
On the afternoon of June 19, Cardiolink Science successfully held“ET PIONEER: Microcatheter Empowers TAME——From Precise Access to MSK Emboliza-tion”Satellite Symposium. The session was chaired by Conference Chair Professor Pierleone Lucatelli, featuring a compact and enriching agenda:
• Opening Remarks: Chairman Che Haibo, in his capacity as a cardiologist, elucidated Cardiolink Science’sTAME(Transcatheter Arterial Microembolization for the Treatment of Musculoskeletal Disorders)Understanding of Mechanisms and Product Portfolio, Emphasizing the Company’s Full-Stack Enablement Capabilities from Micro-guidewires and Micro-catheters to Biodegradable Microspheres.
• Keynote Speech: Dr. Giulio Lombardi from Italy sharedTAMEApplications in Plantar Fasciitis and Epicondylitis, demonstrating robust clinical data—VAS scores for plantar fasciitis decreased from 7.3 to 1.3, and QuickDASH scores for epicondylitis decreased from 50.8 to 2.7. The presentation particularly emphasizedSuperselective CatheterizationandIdentification of Anatomical Variationstechnical key points, as well as the “reversibility” advantage offered by absorbable embolic agents.
• Expert Commentary: Professor Lucatelli and Chairman Che Haibo provided in-depth commentary from the perspectives of clinical value and future directions, respectively. They concurred that with the emergence of new materials such as bioresorbable microspheres, the indications for musculoskeletal (MSK) embolization are expected to be further expanded to include conditions such as arthritis and rotator cuff injuries.
The entire satellite symposium was characterized by a strong academic atmosphere, with Chinese and international experts engaging in lively discussions on topics such as superselective catheterization techniques for target vessels and the selection of embolic agent particle sizes, fully demonstrating Cardiolink Science’sMSKThe Emerging Field of Embolization's Forward-looking Layout and International Influence.
III.Beyond ET: Cardiolink Science’s Global Academic Footprint Is Expanding at an Accelerated Pace
As an enterprise rooted in China and oriented toward the global market, the debut of ET2026 is merely a milestone in Cardiolink Science’s stride toward globalization, with its global academic footprint steadily expanding.
In 2025, Cardiolink Science Successfully Held“Ruijie · Embolization Pioneer Academic Salon”Centered on three key highlights—“Academician-Led · International Perspective, Clinical Practice · Innovative Breakthroughs, Frontier Dialogue · Collaborative Development”—this initiative brings together authoritative experts from China and Japan to focus on the innovative applications of biodegradable microspheres in knee/shoulder joint interventions and other fields, contributing to the promotion of emerging therapies.1。
In May 2026, Cardiolink Science broughtInnovative Technology of Bioresorbable Embolization MicrospheresParticipateThe 9th China-Europe Biomaterials Conference(CESB 2026) – At this premier academic conference co-hosted by the Chinese and European Societies for Biomaterials, the Cardiolink Science team was invited to deliver an oral presentation, showcasing cutting-edge research findings on the application of bioabsorbable embolic microspheres in the treatment of knee osteoarthritis to experts and scholars worldwide.2。
From Valencia to Beijing, from ETTo CESB, Cardiolink Science is actively participating in global academic dialogue in the field of embolization,and put into practice through concrete actions “Extensive Participation in Global Academic Exchanges to Drive Industry Development"this mission."
Note:
[3] The content of this article is intended to help healthcare professionals better understand the latest advances in the relevant disease area, for study and exchange purposes only. The information presented is based on laboratory research findings and shall not replace professional medical guidance in any manner, nor should it be construed as diagnostic or therapeutic advice.
